鶹ý

  • By clicking "OK" or continuing to use this site, you agree that we may collect and use your personal data and set cookies to improve your experience and customise advertising. To see how, and to learn how to control cookies, please read our Privacy Policy and Cookie Policy.
OK
Advertisement
Proactive Investors (Australia)20:03Roche Novo Nordisk Pharma
Kazinform01:19Pfizer Novo Nordisk Pharma
Benzinga10:56Pfizer Novo Nordisk Pharma
Investing.com09:19Novo Nordisk Eli Lilly China
Investopedia13:40Novo Nordisk Eli Lilly China
News-Medical.Net20:52Obesity Health Insulin
Shepherd Express10:55Obesity Health Insulin
The Motley Fool06:00Novo Nordisk Pharma Eli Lilly
Rock Hill Herald17:05FDA Pharma Mounjaro
Women's Health06:21FDA Pharma Mounjaro
Medpage Today01:29Insulin Health Pharma
HealthDay18:19Insulin Health Pharma
In the last 2 hours
Marginal Revolution (Weblog)00:45
Gilmore Health News00:40
In the last 8 hours
Independent Tribune19:45 19-Jul-24
Cageside Seats18:31 19-Jul-24
Yesterday
Digital Journal17:53 19-Jul-24
Rock Hill Herald17:05 19-Jul-24
Independent Tribune13:49 19-Jul-24
Journal of American Medical Associations13:45 19-Jul-24
Investopedia13:40 19-Jul-24
Benzinga13:36 19-Jul-24
American Journal of Managed Care12:59 19-Jul-24
Forbes12:15 19-Jul-24
The Health Foundation11:33 19-Jul-24
Bellingham Herald11:28 19-Jul-24
Heavy.com11:17 19-Jul-24
IFLScience11:00 19-Jul-24
Shepherd Express10:55 19-Jul-24
STAT09:36 19-Jul-24
Kaiser Health News09:33 19-Jul-24
Her.ie09:19 19-Jul-24
Investing.com09:19 19-Jul-24
Independent Tribune08:54 19-Jul-24
Forbes08:16 19-Jul-24
AllAfrica07:51 19-Jul-24
Mint07:39 19-Jul-24
Benzinga07:31 19-Jul-24
Scientific American06:56 19-Jul-24
BNN Bloomberg06:50 19-Jul-24
Women's Health06:21 19-Jul-24
The Motley Fool06:00 19-Jul-24
British Medical Journal05:05 19-Jul-24
Quartz05:01 19-Jul-24
euronews04:21 19-Jul-24
Pinkvilla02:25 19-Jul-24
In the last 7 days
MailOnline23:01 18-Jul-24
The Raw Story21:27 18-Jul-24
Miami Herald21:26 18-Jul-24
News-Medical.Net20:52 18-Jul-24
Proactive Investors (Australia)20:03 18-Jul-24
Benzinga17:08 18-Jul-24
The Kansas City Star16:58 18-Jul-24
The Hollywood Gossip15:39 18-Jul-24
Rock Hill Herald15:37 18-Jul-24
Independent Tribune12:23 18-Jul-24
PRWeb (Press Release)11:08 18-Jul-24
KDRTV10:51 18-Jul-24
Zacks10:38 18-Jul-24
Biopharma Reporter10:14 18-Jul-24
Biopharma Reporter10:14 18-Jul-24
Biopharma Reporter10:14 18-Jul-24
Knowridge Science Report09:15 18-Jul-24
FoodBev Media08:35 18-Jul-24
Prevention.com08:35 18-Jul-24
RTE07:51 18-Jul-24
British Medical Journal05:41 18-Jul-24
ParentData05:01 18-Jul-24
ParentData05:01 18-Jul-24
Muse by Clio04:25 18-Jul-24
Albawaba02:41 18-Jul-24
Kazinform01:19 18-Jul-24
Vogue Business00:34 18-Jul-24
MailOnline23:49 17-Jul-24
Cleveland 1918:27 17-Jul-24
Japan Today17:41 17-Jul-24
XXLMag.com17:41 17-Jul-24
Yahoo! US17:22 17-Jul-24
Forbes17:05 17-Jul-24
Fox News16:59 17-Jul-24
ScreenRant15:52 17-Jul-24
Independent Tribune15:12 17-Jul-24
Independent Tribune14:21 17-Jul-24
Nicki Swift14:09 17-Jul-24
Benzinga13:50 17-Jul-24
The Daily Caller13:27 17-Jul-24
The Motley Fool13:26 17-Jul-24
MailOnline13:18 17-Jul-24
DoYouRemember?13:04 17-Jul-24
Proactive Investors (UK)12:21 17-Jul-24
In Touch Weekly Magazine12:09 17-Jul-24
New Scientist12:04 17-Jul-24
Goodtoknow.co.uk11:50 17-Jul-24
Quartz11:06 17-Jul-24
Benzinga10:56 17-Jul-24
Benzinga10:56 17-Jul-24
Investopedia10:50 17-Jul-24
Pharmaceutical Technology10:45 17-Jul-24
Sooke News Mirror10:11 17-Jul-24
Independent Tribune09:56 17-Jul-24
People09:48 17-Jul-24
Independent Tribune09:46 17-Jul-24
CBC.ca09:07 17-Jul-24
Food Politics09:02 17-Jul-24
The Independent08:42 17-Jul-24
BNN Bloomberg08:24 17-Jul-24
GlobeNewswire (Press Release)07:53 17-Jul-24
Irish Examiner07:38 17-Jul-24
Forbes07:15 17-Jul-24
WIRED07:06 17-Jul-24
naked capitalism06:58 17-Jul-24
News-Medical.Net06:04 17-Jul-24
pharmaphorum05:28 17-Jul-24
STAT04:42 17-Jul-24
Pinkvilla04:22 17-Jul-24
CounterPunch02:01 17-Jul-24
Medpage Today01:29 17-Jul-24
Medpage Today01:29 17-Jul-24
Women's Wear Daily01:07 17-Jul-24
Pharmaceutical Technology00:14 17-Jul-24
KBTX19:02 16-Jul-24
Entertainment Tonight18:45 16-Jul-24
Pharmacy Times17:33 16-Jul-24
Science 2.016:30 16-Jul-24
The Kansas City Star15:00 16-Jul-24
Media News Group14:30 16-Jul-24
Supermarket News14:15 16-Jul-24
view more headlines
20 Jul 00:45

About our Ozempic news

Latest news on Ozempic, Wegovy, Rybelsus: semaglutide weight loss drugs making headlines for remarkable results, high demand, and celebrity use. Stay updated on these popular GLP-1 medications.

Ozempic, Wegovy, and Rybelsus are brand names for semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist originally developed for type 2 diabetes treatment. These injectable and oral medications have gained significant attention for their impressive weight loss effects, with many users reporting rapid and substantial body weight reductions. As a result, demand for semaglutide drugs has skyrocketed, leading to shortages and waiting lists in some areas.

Our semaglutide news feed brings you the latest updates on these groundbreaking weight loss drugs from reliable medical sources, pharmaceutical companies like Novo Nordisk, and real-world patient experiences. Stay informed about the efficacy, safety, and potential side effects of Ozempic, Wegovy, and Rybelsus, as well as ongoing clinical trials and research into their long-term effects and potential new applications.

In addition to their medical aspects, semaglutide drugs have become a cultural phenomenon, with celebrities and influencers openly discussing their use of Ozempic and Wegovy for weight loss. Our feed covers these high-profile endorsements and the ensuing public discourse about the ethics and accessibility of these treatments. We also explore the societal implications of the growing popularity of semaglutide, including its impact on body image standards and the potential for exacerbating existing inequalities in healthcare access.

As the demand for Ozempic, Wegovy, and Rybelsus continues to grow, our feed keeps you updated on supply chain issues, regulatory developments, and efforts by manufacturers to ramp up production and expand availability. We also cover debates surrounding insurance coverage for these weight loss drugs and the evolving policies of healthcare providers and payers.

With obesity rates on the rise globally, the advent of effective weight loss medications like semaglutide has significant implications for public health and healthcare systems. Our semaglutide news feed delves into these broader contexts, exploring the potential of these drugs to combat the obesity epidemic and their role in comprehensive weight management strategies alongside lifestyle changes and other interventions.

Stay at the forefront of the rapidly evolving landscape of semaglutide weight loss treatments with our continuously updated Ozempic, Wegovy, and Rybelsus news feed. Whether you're a healthcare professional, a person struggling with obesity, or simply interested in this groundbreaking development, our feed is your go-to source for comprehensive, nuanced coverage of these remarkable drugs.


Publication filters

Headline Density

Sorry, no headlines or news topics were found. Please try different keywords.